Evidence map›Paper›PMID 34657125›Full record

ArticleBlood cancer journal2021

Characteristics and outcome of acute myeloid leukemia with uncommon retinoic acid receptor-alpha (RARA) fusion variants.

Laura Cicconi, Anna Maria Testi, Pau Montesinos, Eduardo Rego, Hong Hu Zhu, Hiroyuki Takahashi, Michael Dworzak, Elihu Estey, Anthony Schwarer, Jordi Esteve and 13 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Experiences of Discrimination and DNA Methylation Among Black Nulliparous Women.Journal of racial and ethnic health disparities · 2026
    Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Function of PML-RARA in Acute Promyelocytic Leukemia.Advances in experimental medicine and biology · 2024
    Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Case Report: Identification of a novelFrontiers in oncology · 2023
    Article
  12. Review
  13. Review
  14. Case Report: Successful therapy with all-Frontiers in oncology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Laura CicconiDepartment of Biomedicine and Prevention, University Tor Vergata, Rome, Italy. cicconi.laura@yahoo.it.ORCID 0000-0001-5642-3051
Anna Maria TestiDepartment of Translational and Precision Medicine and Hematology, 'Sapienza' University, Rome, Italy.ORCID 0000-0003-2138-4894
Pau MontesinosDepartment of Hematology, Hospital Universitari i Politècnico la Fe, València, Spain.ORCID 0000-0002-3275-5593
Eduardo RegoDepartment of Internal Medicine, Medical School of Ribeirao Preto, Ribeirao Preto, Brazil.
Hong Hu ZhuDepartment of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.ORCID 0000-0003-2343-0436
Hiroyuki TakahashiDepartment of Pediatrics, Toho University, Tokyo, Japan.
Michael DworzakChildren's Cancer Research Institute and St Anna Children's Hospital, Department of Pediatrics, Medical University of Vienna, Vienna, Austria.
Elihu EsteyClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Anthony SchwarerDepartment of Hematology and Oncology, Eastern School, Monash University, Melbourne, VIC, Australia.
Jordi EsteveServicio de Hematología, Instituto Clínic de Enfermedades Hematológicas y Oncológicas, Hospital Clínic de Barcelona, Barcelona, Spain.ORCID 0000-0002-8056-648X
Ombretta AnnibaliHematology and Stem Cells Transplantation Unit, University Campus Bio-Medico, Rome, Italy.
Roberto CastelliDepartment of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Luigi Sacco Hospital, Milano, Italy.
Milena MirabileHematologyUnit, Ospedale di Civitanova Marche, Macerata, Italy.
Mario AngeliniHematology Unit, Ospedale Mazzoni, Ascoli Piceno, Italy.
Vladimir LazarevicDepartment of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden.ORCID 0000-0002-1782-4423
Jeevan KumarDepartment of Clinical Haematology and BMT Tata Medical Center, Kolkata, India.ORCID 0000-0002-5230-1214
Giuseppe AvvisatiHematology and Stem Cells Transplantation Unit, University Campus Bio-Medico, Rome, Italy.
Carmelo GurnariDepartment of Biomedicine and Prevention, University Tor Vergata, Rome, Italy.ORCID 0000-0001-6829-5544
Franco LocatelliDepartment of Pediatric Hematology/Oncology, IRCCS Ospedale Pediatrico Bambino Gesu, Rome, Italy.
Maria Teresa VosoDepartment of Biomedicine and Prevention, University Tor Vergata, Rome, Italy.ORCID 0000-0002-6164-4761
Miguel Angel SanzDepartment of Hematology, Hospital Universitari i Politècnico la Fe, València, Spain.ORCID 0000-0003-1489-1177
Francesco Lo-CocoDepartment of Biomedicine and Prevention, University Tor Vergata, Rome, Italy.
Oussama AblaDivision of Hematology/Oncology, Department of Pediatrics, the Hospital for Sick Children, University of Toronto, Toronto, ON, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdolescentAdultAgedAged, 80 and overChildChild, PreschoolDisease-Free SurvivalFemaleHumansLeukemia, Promyelocytic, AcuteMaleMiddle AgedOncogene Proteins, FusionRetinoic Acid Receptor alphaSurvival RateOncogene Proteins, FusionRARA protein, humanRetinoic Acid Receptor alpha

Identifiers

PMID34657125
PMCPMC8520532

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.